TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0

Historical Holders from Q1 2022 to Q3 2025

Type / Class
Debt / NOTE 2.250% 3/0
All holders as of 30 Sep 2025
Q3 2025
Total 13F principal, excl. options
272,401,354
Holdings value
$307,917,277
% of all portfolios
0%
Number of holders
29
Number of buys
13
Number of sells
-14
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0

Period Principal Value Change Price Investors
2025 Q3 272,401,354 $307,917,277 +$569,601 $1.13 29
2025 Q2 279,664,978 $303,344,890 +$1,782,692 $0.9539 26
2025 Q1 277,011,293 $276,983,110 +$13,929,020 $0.998 28
2024 Q4 264,062,863 $250,352,690 +$9,069,609 $0.9524 21
2024 Q3 257,683,037 $224,077,029 +$11,645,577 $0.864 25
2024 Q2 253,865,742 $203,588,240 -$12,098,839 $0.6479 18
2024 Q1 273,167,017 $213,304,940 -$34,119,308,890 $0.6347 18
2023 Q4 334,700,000 $220,380,890 +$27,118,701 $0.66 20
2023 Q3 293,624,167 $216,434,339 +$1,578,777 $0.6472 22
2023 Q2 302,112,167 $244,546,345 -$10,623,621 $0.8108 21
2023 Q1 312,983,167 $325,418,603 +$10,031,881 $0.983 21
2022 Q4 301,166,967 $274,825,761 -$26,924,802 $0.9119 21
2022 Q3 282,429,300 $289,316,637 -$825,518 $1.02 23
2022 Q2 239,416,100 $244,284,801 -$22,593,875 $1 21
2022 Q1 257,273,349 $279,703,965 +$279,703,965 $1.06 23